<DOC>
	<DOC>NCT02713893</DOC>
	<brief_summary>The primary objective of the study is to evaluate local tolerability of the new Econazole/Benzydamine product, in comparison with the Econazole and Benzydamine stand-alone products and placebo. Pharmacokinetics of the study products after single and repeated applications once a day for 15 days, safety of the investigational products and comfort of use will also be evaluated as secondary objectives.</brief_summary>
	<brief_title>Tolerability and Pharmacokinetic Study of Econazole Nitrate and Benzydamine HCl Intravaginal Cream</brief_title>
	<detailed_description />
	<mesh_term>Benzydamine</mesh_term>
	<mesh_term>Econazole</mesh_term>
	<criteria>1. Informed consent: signed written informed consent before inclusion in the study; 2. Sex and age: females, aged 1855 years old inclusive; 3. Body Mass Index (BMI): 18.530 kg/m2 inclusive; 4. Vital signs: systolic blood pressure 100139 mmHg, diastolic blood pressure 5089 mmHg, heart rate 5090 bpm, measured after 5 min at rest (sitting position); 5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to cooperate with the investigator and to comply with the requirements of the entire study; 6. Sexual abstinence: agreement to sexual abstinence during the study; 7. Contraception and fertility: women of childbearing potential, even if sexual abstinent during the study as required by the study inclusion criteria, must be using at least one reliable method of contraception, as follows: 1. hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit; 2. a nonhormonal intrauterine device [IUD] for at least 2 months before the screening visit; 3. a male sexual partner who agrees to use a male condom; 4. a vasectomised sexual partner. Female participants of nonchildbearing potential will be admitted. For all female subjects, pregnancy test result must be negative at screening and at each scheduled evaluation; 8. PAP test: negative result at PAP test (i.e. normal PAP test result without atypical cells) at screening. 1. ECG (12leads, supine position): clinically significant abnormalities; 2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study as judged by the investigator; 3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness; 4. Allergy: ascertained or presumptive hypersensitivity (including allergies) to the active ingredients (econazole and/ or benzydamine) and/or formulations' excipients or related drugs, e.g. other azoles; history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study; 5. Diseases: relevant history of renal, hepatic, gastrointestinal, genitourinary, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study or affect the subject's safety; 6. Genitourinary disease: presence of any specific genitourinary symptoms detected at Visit 2 with the relevant questionnaire (genitourinary symptoms questionnaire); 7. Infection history: history of bacterial urinary tract or bacterial and fungal vaginal infections for 3 weeks before the screening visit; 8. Infections: bacterial or fungal infections (microbiology assessment); 9. Gynaecological findings: clinically significant abnormal findings at the gynaecological visit performed by the study gynaecologist; 10. Mucosa conditions: altered mucosa conditions affecting the site of application (e.g. open lesion or other); 11. Vaginal conditions: use of vaginal detergents, soaps and washes that, in the investigator's opinion, may have an influence on vaginal pH and/or change the vaginal flora; 12. Medications: any medication (topical or systemic), including over the counter, herbal medication, topical drugs on the application area and anticoagulants, such as warfarin and acenocoumarol, for 2 weeks before the start of the study. Hormonal contraceptives and hormonal replacement therapies are allowed. Paracetamol will be allowed as a countermeasure for adverse events, on a case by case basis, if deemed appropriate by the investigator; 13. Investigative drug studies: participation in the evaluation of any drug for 3 months before this study, calculated from the first day of the month following the last visit of a previous study and the first day of the present study (date of the informed consent signature); 14. Blood donation: blood donations for 3 months before this study; 15. Drug, alcohol, caffeine, tobacco: history of drug, alcohol (&gt; 1 drink/day, defined according to USDA Dietary Guidelines 2010), tobacco (â‰¥ 10 cigarettes/day) or caffeine (&gt; 5 cups coffee/tea/day) abuse; 16. Diet: Abnormal diets (&lt; 1600 or &gt; 3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study; vegetarians 17. Pregnancy: positive or missing pregnancy test at screening or day 1, pregnant or lactating women or females of childbearing potential not following adequate contraceptive procedures; 18. Noncompliance: subjects suspected to have a high potential for noncompliance to the study procedures according to the investigator's judgement, including noncompliance to sexual abstinence during the study; 19. Drug test (cocaine, amphetamine, methamphetamine, cannabinoids, opiates and ecstasy): positive result at the drug test at screening 20. Alcohol test: positive alcohol breath test at day 1</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Econazole nitrate 1%</keyword>
	<keyword>Benzydamine HCl 0.12%</keyword>
	<keyword>Intravaginal cream</keyword>
	<keyword>Antimycotic</keyword>
	<keyword>Tolerability</keyword>
</DOC>